JYJirundon Yuvaniyama

Jirundon Yuvaniyama

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jirundon Yuvaniyama has a total of 95 co-authors. Here are the top co-authors by number of shared publications:

  • Yongyuth Yuthavong

    National Center for Genetic Engineering and Biotechnology (BIOTEC), National Science and Technology Development Agency (NSTDA), 113 Thailand Science Park, Khlong Nueng, Khlong Luang, Pathum Thani 12120, Thailand

    9 shared publications
  • Sumalee Kamchonwongpaisan

    BIOTEC, National Science and Technology Development Agency, Thailand Science Park, Pathumthani 12120, Thailand

    6 shared publications
  • Jarunee Vanichtanankul

    BIOTEC, National Science and Technology Development Agency, Thailand Science Park, Pathumthani 12120, Thailand

    5 shared publications
  • Jisnuson Svasti

    Laboratory of Biochemistry, Chulabhorn Research Institute, Bangkok, Thailand

    5 shared publications
  • Robert Charles Robinson

    School of Biomolecular Science and Engineering (BSE), Vidyasirimedhi Institute of Science and Technology (VISTEC), Rayong, Thailand

    4 shared publications
  • James R. Ketudat Cairns

    Center for Biomolecular Structure, Function and Application and School of Chemistry, Institute of Science, Suranaree University of Technology, Nakhon Ratchasima 30000, Thailand

    3 shared publications

Latest Publications

  • Open Access

    Capturing Catalysis: Structural Insights into the Acyl-Enzyme Intermediate of Priestia megaterium Penicillin G Acylase

    by Chanisara Kaewsasan, Catleya Rojviriya, Worrapoj Oonanant, Nudhchaphud Prathumrat, Wilailuk Koinueng, Jirundon Yuvaniyama

    Penicillin G acylase (PGA) is a key biocatalyst in the synthesis of semisynthetic β-lactam antibiotics. We herein report three high-resolution crystal structures of Priestia megaterium PGA (PmPGA), capturing the enzyme in distinct catalytic states: the ligand-free form, the enzyme–product complex (PmPGA–PAA), and the covalent acyl-enzyme intermediate (PmPGA–PAX). These structures provide direct structural evidence for the proposed two-step catalytic mechanism and offer insights into the roles of active-site residues and water molecules in catalysis. The nucleophilic Ser1β, whose catalytic role is well established, is activated by its α-amino group and stabilized by Gln23β and Asn245β, while Ala69β and Asn245β form the oxyanion hole. Water molecules at the Wat1 position appear to mediate proton transfer and nucleophilic attack during acylation and deacylation, respectively. Structural comparisons with Escherichia coli PGA (EcPGA) highlight both conserved features and adaptations in PmPGA, including a shorter active-site loop and a second calcium-binding site. Notably, PmPGA selectively recognizes the side chain of its substrate rather than the β-lactam core, suggesting a distinct substrate specificity that can be leveraged for the design of tailored biocatalysts. These findings deepen our understanding of Ntn hydrolase catalysis and establish PmPGA as a promising scaffold for engineering next-generation enzymes for β-lactam antibiotic synthesis.

  • MANORAA: A machine learning platform to guide protein-ligand design by anchors and influential distances

    by Duangrudee Tanramluk, Danaya Pakotiprapha, Sakao Phoochaijaroen, Pattra Chantravisut, Sirikanya Thampradid, Jarunee Vanichtanankul, Lalita Narupiyakul, Ruj Akavipat, Jirundon Yuvaniyama


  • Open Access

    Disulfide Linkages in Plasmodium falciparum Plasmepsin-I Are Essential Elements for Its Processing Activity and Multi-Milligram Recombinant Production Yield

    by Sirisak Lolupiman, Pilaiwan Siripurkpong, Jirundon Yuvaniyama

    Plasmodium falciparum plasmepsin-I (PM-I) has been considered a potential drug target for the parasite that causes fatal malaria in human. Determination of PM-I structures for rational design of its inhibitors is hindered by the difficulty in obtaining large quantity of soluble enzyme. Nearly all attempts for its heterologous expression in Escherichia coli result in the production of insoluble proteins in both semi-pro-PM-I and its truncated form, and thus require protein refolding. Moreover, the yields of purified, soluble PM-I from all reported studies are very limited. Exclusion of truncated semi-pro-PM-I expression in E. coli C41(DE3) is herein reported. We also show that the low preparation yield of purified semi-pro-PM-I with autoprocessing ability is mainly a result of structural instability of the refolded enzyme in acidic conditions due to incomplete formation of disulfide linkages. Upon formation of at least one of the two natural disulfide bonds, nearly all of the refolded semi-pro-PM-I could be activated to its mature form. A significantly improved yield of 10 mg of semi-pro-PM-I per liter of culture, which resulted in 6–8 mg of the mature PM-I, was routinely obtained using this strategy.


  • Open Access

    Functional expression of a Bombyx mori cocoonase: potential application for silk degumming

    by Prangprapai Rodbumrer, Dumrongkiet Arthan, Utai Uyen, Jirundon Yuvaniyama, Jisnuson Svasti, Pramvadee Y. Wongsaengchantra

    Cocoon, a shelter for larva development to silk moth, contains the fibrous protein fibroin, which is coated by the globular protein sericin. Emergence of the silk moth requires the action of cocoonase, a protease secreted by the pupa. The full-length prococoonase cDNA, with 780 bp open reading frame encoding 260 amino acids, was cloned by reverse transcription from total RNA of the head of 6-day-old Thai-silk Bombyx mori pupa. Only the gene fragment lacking the propeptide encoding sequence was successfully expressed in Pichia pastoris, yielding an extracellularly active cocoonase. The recombinant cocoonase was purified to homogeneity by 80% ammonium-sulfate fractionation and CM-Sepharose chromatography, and its internal peptide sequences were analyzed by nano liquid chromatography-mass spectrometry/mass spectrometry. This monomeric protein has native molecular weight of 26 kDa by gel exclusion analysis and 25 kDa subunit size by sodium dodecyl sulphate-polyacrylamide gel electrophoresis. The enzyme hydrolyses sericin but does not hydrolyse fibroin, as shown by radial diffusion on thin-layer enzyme assay (RD-TEA). Scanning electron microscopy showed that purified recombinant cocoonase could remove sericin from natural silk completely in 24 h, without damaging fibroin, using only 1 immobilized sericin unit (ISU) of enzyme as determined by RD-TEA. Natural cocoonase isolated from B. mori pupa could also digest sericin effectively, but required more enzymes (2 ISU) and longer time (48 h). In comparison, a commercial enzyme, alcalase, with the same activity not only showed less complete digestion of sericin but also caused damage of fibroin. These results suggest that recombinant B. mori cocoonase is potentially useful for silk degumming.


  • Malarial dihydrofolate reductase as a paradigm for drug development against a resistance-compromised target

    by Yongyuth Yuthavong, Bongkoch Tarnchompoo, Tirayut Vilaivan, Penchit Chitnumsub, Sumalee Kamchonwongpaisan, Susan A. Charman, Danielle N. McLennan, Karen L. White, Livia Vivas, Emily Bongard, et al.

    Malarial dihydrofolate reductase (DHFR) is the target of antifolate antimalarial drugs such as pyrimethamine and cycloguanil, the clinical efficacy of which have been compromised by resistance arising through mutations at various sites on the enzyme. Here, we describe the use of cocrystal structures with inhibitors and substrates, along with efficacy and pharmacokinetic profiling for the design, characterization, and preclinical development of a selective, highly efficacious, and orally available antimalarial drug candidate that potently inhibits both wild-type and clinically relevant mutated forms of Plasmodium falciparum (Pf) DHFR. Important structural characteristics of P218 include pyrimidine side-chain flexibility and a carboxylate group that makes charge-mediated hydrogen bonds with conserved Arg122 (PfDHFR-TS amino acid numbering). An analogous interaction of P218 with human DHFR is disfavored because of three species-dependent amino acid substitutions in the vicinity of the conserved Arg. Thus, P218 binds to the active site of PfDHFR in a substantially different fashion from the human enzyme, which is the basis for its high selectivity. Unlike pyrimethamine, P218 binds both wild-type and mutant PfDHFR in a slow-on/slow-off tight-binding mode, which prolongs the target residence time. P218, when bound to PfDHFR-TS, resides almost entirely within the envelope mapped out by the dihydrofolate substrate, which may make it less susceptible to resistance mutations. The high in vivo efficacy in a SCID mouse model of P. falciparum malaria, good oral bioavailability, favorable enzyme selectivity, and good safety characteristics of P218 make it a potential candidate for further development.


  • Open Access

    The C-terminal Domain of 4-Hydroxyphenylacetate 3-Hydroxylase from Acinetobacter baumannii Is an Autoinhibitory Domain

    by Thanawat Phongsak, Jeerus Sucharitakul, Kittisak Thotsaporn, Worrapoj Oonanant, Jirundon Yuvaniyama, Jisnuson Svasti, David P. Ballou, Pimchai Chaiyen


  • Open Access

    Crystallization and preliminary X-ray analysis of the reductase component ofp-hydroxyphenylacetate 3-hydroxylase fromAcinetobacter baumannii

    by Worrapoj Oonanant, Jeerus Sucharitakul, Pimchai Chaiyen, Jirundon Yuvaniyama

    p-Hydroxyphenylacetate 3-hydroxylase (HPAH) from Acinetobacter baumannii catalyzes the hydroxylation of p-hydroxyphenylacetate (HPA) at the ortho position to yield 3,4-dihydroxyphenylacetate (DHPA). HPAH from A. baumannii is a two-component flavoprotein consisting of a smaller reductase (C1) component and a larger oxygenase (C2) component. The C1 component supplies a reduced flavin in its free form to the C2 counterpart for hydroxylation. In addition, HPA can bind to C1 and enhance the flavin-reduction rate without becoming hydroxylated. The recombinant C1 component was purified and crystallized using the microbatch method at 295 K. X-ray diffraction data were collected to 2.3 Å resolution using synchrotron radiation on the BL13B1 beamline at NSRRC, Taiwan. The crystal belonged to the orthorhombic space group P212121, with unit-cell parameters a = 47.78, b = 59.92, c = 211.85 Å, and contained two molecules of C1 per asymmetric unit.


  • Improved X-ray diffraction from Bacillus megaterium penicillin G acylase crystals through long cryosoaking dehydration

    by Catleya Rojviriya, Thunyaluck Pratumrat, Mark A. Saper, Jirundon Yuvaniyama

    Penicillin G acylase from Bacillus megaterium (BmPGA) is currently used in the pharmaceutical industry as an alternative to PGA from Escherichia coli (EcPGA) for the hydrolysis of penicillin G to produce 6-aminopenicillanic acid (6-APA), a penam nucleus for semisynthetic penicillins. Despite the significant differences in amino-acid sequence between PGAs from Gram-positive and Gram-negative bacteria, a representative PGA structure of Gram-positive origin has never been reported. In this study, crystallization and diffraction studies of BmPGA are described. Poor diffraction patterns with blurred spots at higher resolution were typical for BmPGA crystals cryocooled after a brief immersion in cryoprotectant solution. Overnight soaking in the same cryo-solution substantially improved both the mosaicity and resolution limit through the establishment of a new crystal-packing equilibrium. A crystal of BmPGA diffracted X-rays to 2.20 Å resolution and belonged to the monoclinic space group P21 with one molecule of BmPGA in the asymmetric unit.


  • Trypanosomal Dihydrofolate Reductase Reveals Natural Antifolate Resistance

    by Jarunee Vanichtanankul, Supannee Taweechai, Jirundon Yuvaniyama, Tirayut Vilaivan, Penchit Chitnumsub, Sumalee Kamchonwongpaisan, Yongyuth Yuthavong

    Dihydrofolate reductase (DHFR) is a potential drug target for Trypanosoma brucei, a human parasite, which is the causative agent for African sleeping sickness. No drug is available against this target, since none of the classical antifolates such as pyrimethamine (PYR), cycloguanil, or trimethoprim are effective as selective inhibitors of T. brucei DHFR (TbDHFR). In order to design effective drugs that target TbDHFR, co-crystal structures with bound antifolates were studied. On comparison with malarial Plasmodium falciparum DHFR (PfDHFR), the co-crystal structures of wild-type TbDHFR reveal greater structural similarities to a mutant PfDHFR causing antifolate resistance than the wild-type enzyme. TbDHFR imposes steric hindrance for rigid inhibitors like PYR around Thr86, which is equivalent to Ser108Asn of the malarial enzymes. In addition, a missing residue on TbDHFR active-site loop together with the presence of Ile51 widens its active site even further than the structural effect of Asn51Ile, which is observed in PfDHFR structures. The structural similarities are paralleled by the similarly poor affinities of the trypanosomal enzyme for rigid inhibitors. Mutations of TbDHFR at Thr86 resulted in 10-fold enhancement or 7-fold reduction in the rigid inhibitors affinities for Thr86Ser or Thr86Asn, respectively. The co-crystal structure of TbDHFR with a flexible antifolate WR99210 suggests that its greater affinity result from its ability to avoid such Thr86 clash and occupy the widened binding space similarly to what is observed in the PfDHFR structures. Natural resistance to antifolates of TbDHFR can therefore be explained, and potential antifolate chemotherapy of trypanosomiasis should be possible taking this into account.